Cargando…

Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart

Previous studies have shown that glucagon-like peptide-1 (GLP-1) provides cardiovascular benefits independent of its role on peripheral glycemic control. However, the precise mechanism(s) by which GLP-1 treatment renders cardioprotection during myocardial ischemia remain unresolved. Here we examined...

Descripción completa

Detalles Bibliográficos
Autores principales: Aravindhan, Karpagam, Bao, Weike, Harpel, Mark R., Willette, Robert N., Lepore, John J., Jucker, Beat M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476748/
https://www.ncbi.nlm.nih.gov/pubmed/26098939
http://dx.doi.org/10.1371/journal.pone.0130894
_version_ 1782377647722987520
author Aravindhan, Karpagam
Bao, Weike
Harpel, Mark R.
Willette, Robert N.
Lepore, John J.
Jucker, Beat M.
author_facet Aravindhan, Karpagam
Bao, Weike
Harpel, Mark R.
Willette, Robert N.
Lepore, John J.
Jucker, Beat M.
author_sort Aravindhan, Karpagam
collection PubMed
description Previous studies have shown that glucagon-like peptide-1 (GLP-1) provides cardiovascular benefits independent of its role on peripheral glycemic control. However, the precise mechanism(s) by which GLP-1 treatment renders cardioprotection during myocardial ischemia remain unresolved. Here we examined the role for GLP-1 treatment on glucose and fatty acid metabolism in normal and ischemic rat hearts following a 30 min ischemia and 24 h reperfusion injury, and in isolated cardiomyocytes (CM). Relative carbohydrate and fat oxidation levels were measured in both normal and ischemic hearts using a 1-(13)C glucose clamp coupled with NMR-based isotopomer analysis, as well as in adult rat CMs by monitoring pH and O(2) consumption in the presence of glucose or palmitate. In normal heart, GLP-1 increased glucose uptake (↑64%, p<0.05) without affecting glycogen levels. In ischemic hearts, GLP-1 induced metabolic substrate switching by increasing the ratio of carbohydrate versus fat oxidation (↑14%, p<0.01) in the LV area not at risk, without affecting cAMP levels. Interestingly, no substrate switching occurred in the LV area at risk, despite an increase in cAMP (↑106%, p<0.05) and lactate (↑121%, p<0.01) levels. Furthermore, in isolated CMs GLP-1 treatment increased glucose utilization (↑14%, p<0.05) and decreased fatty acid oxidation (↓15%, p<0.05) consistent with in vivo finding. Our results show that this benefit may derive from distinct and complementary roles of GLP-1 treatment on metabolism in myocardial sub-regions in response to this injury. In particular, a switch to anaerobic glycolysis in the ischemic area provides a compensatory substrate switch to overcome the energetic deficit in this region in the face of reduced tissue oxygenation, whereas a switch to more energetically favorable carbohydrate oxidation in more highly oxygenated remote regions supports maintaining cardiac contractility in a complementary manner.
format Online
Article
Text
id pubmed-4476748
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-44767482015-06-25 Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart Aravindhan, Karpagam Bao, Weike Harpel, Mark R. Willette, Robert N. Lepore, John J. Jucker, Beat M. PLoS One Research Article Previous studies have shown that glucagon-like peptide-1 (GLP-1) provides cardiovascular benefits independent of its role on peripheral glycemic control. However, the precise mechanism(s) by which GLP-1 treatment renders cardioprotection during myocardial ischemia remain unresolved. Here we examined the role for GLP-1 treatment on glucose and fatty acid metabolism in normal and ischemic rat hearts following a 30 min ischemia and 24 h reperfusion injury, and in isolated cardiomyocytes (CM). Relative carbohydrate and fat oxidation levels were measured in both normal and ischemic hearts using a 1-(13)C glucose clamp coupled with NMR-based isotopomer analysis, as well as in adult rat CMs by monitoring pH and O(2) consumption in the presence of glucose or palmitate. In normal heart, GLP-1 increased glucose uptake (↑64%, p<0.05) without affecting glycogen levels. In ischemic hearts, GLP-1 induced metabolic substrate switching by increasing the ratio of carbohydrate versus fat oxidation (↑14%, p<0.01) in the LV area not at risk, without affecting cAMP levels. Interestingly, no substrate switching occurred in the LV area at risk, despite an increase in cAMP (↑106%, p<0.05) and lactate (↑121%, p<0.01) levels. Furthermore, in isolated CMs GLP-1 treatment increased glucose utilization (↑14%, p<0.05) and decreased fatty acid oxidation (↓15%, p<0.05) consistent with in vivo finding. Our results show that this benefit may derive from distinct and complementary roles of GLP-1 treatment on metabolism in myocardial sub-regions in response to this injury. In particular, a switch to anaerobic glycolysis in the ischemic area provides a compensatory substrate switch to overcome the energetic deficit in this region in the face of reduced tissue oxygenation, whereas a switch to more energetically favorable carbohydrate oxidation in more highly oxygenated remote regions supports maintaining cardiac contractility in a complementary manner. Public Library of Science 2015-06-22 /pmc/articles/PMC4476748/ /pubmed/26098939 http://dx.doi.org/10.1371/journal.pone.0130894 Text en © 2015 Aravindhan et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Aravindhan, Karpagam
Bao, Weike
Harpel, Mark R.
Willette, Robert N.
Lepore, John J.
Jucker, Beat M.
Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart
title Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart
title_full Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart
title_fullStr Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart
title_full_unstemmed Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart
title_short Cardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat Heart
title_sort cardioprotection resulting from glucagon-like peptide-1 administration involves shifting metabolic substrate utilization to increase energy efficiency in the rat heart
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4476748/
https://www.ncbi.nlm.nih.gov/pubmed/26098939
http://dx.doi.org/10.1371/journal.pone.0130894
work_keys_str_mv AT aravindhankarpagam cardioprotectionresultingfromglucagonlikepeptide1administrationinvolvesshiftingmetabolicsubstrateutilizationtoincreaseenergyefficiencyintheratheart
AT baoweike cardioprotectionresultingfromglucagonlikepeptide1administrationinvolvesshiftingmetabolicsubstrateutilizationtoincreaseenergyefficiencyintheratheart
AT harpelmarkr cardioprotectionresultingfromglucagonlikepeptide1administrationinvolvesshiftingmetabolicsubstrateutilizationtoincreaseenergyefficiencyintheratheart
AT willetterobertn cardioprotectionresultingfromglucagonlikepeptide1administrationinvolvesshiftingmetabolicsubstrateutilizationtoincreaseenergyefficiencyintheratheart
AT leporejohnj cardioprotectionresultingfromglucagonlikepeptide1administrationinvolvesshiftingmetabolicsubstrateutilizationtoincreaseenergyefficiencyintheratheart
AT juckerbeatm cardioprotectionresultingfromglucagonlikepeptide1administrationinvolvesshiftingmetabolicsubstrateutilizationtoincreaseenergyefficiencyintheratheart